Seattle Genetics’ Revenue Rises 19% on Adcetris Sales Growth | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 1 May, 2014 by The TZ Newswire Staff

Seattle Genetics’ Revenue Rises 19% on Adcetris Sales Growth

Antibody-drug conjugate developer Seattle Genetics delivers strong sales gains from lead drug Adcetris despite a flat year-over-year net loss.

See also
- Next Article Why Shares of Gentherm Inc Were Heating Up Today
- Previous Article Ukraine Admits "Helpless" Against Pro-Russian Forces; Reinstates Military Conscription
Editorial Calender

May 2014

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30 31

« Jun Jun »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar